ID: MRFR/LS/5312-HCR | February 2023 | Region: Global | 100 Pages
The Mycoplasma Testing Market is expected to grow significantly CAGR of 13.9% and market held a value of USD 2.18 billion over the forecast period
$2.18 billion
13.9%
North America
2022-2030
Mycoplasma Testing Market Overview:
The mycoplasma testing market size was valued USD 798.7 million in 2021 and is expected to reach USD 2.18 billion by 2030 at 13.9% CAGR during the forecast period 2022-2030. Mycoplasma testing is used to detect contamination in a biological sample. Increasing R&D costs and new product releases are projected to drive the growth of the mycoplasma testing market. However, the availability of alternative conventional methods will impede the growth of the mycoplasma testing market over the projection period. The mycoplasma testing market is divided into three categories: product, technique, and application. The market is divided into three categories: kits and reagents, instruments, and services. In 2017, the kits and reagents category is predicted to account for the greatest proportion of the market.
Key players:
Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Thermo Fisher Scientific Inc., Promocell GmbH are some of the key players in the mycoplasma testing market.Â
Market Segmentation:
The mycoplasma testing market has been segmented into product, Technique, and application.
Based on product, market segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share segment of the market in 2017.
Based on Technique, market segmented into DNA Stain, Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.
Based on application, market segmented into cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.
Based on end user, market segmented into pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The mycoplasma testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European mycoplasma testing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The mycoplasma testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The mycoplasma testing market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the mycoplasma testing market owing to a well-established player and increasing R&D expenses.
Europe is expected to hold the second largest position in the mycoplasma testing market. The market growth in this region is attributed to the growth in pharmaceutical and medical devices industry.
The mycoplasma testing market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing adoption of these products.
The Middle East & Africa has the least share of the market.
By Product
By Technique
By Application
By End User
By Region
The report for Mycoplasma Testing Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Recent Development
Lonza Group Ltd (Lonza) is a corporation that provides contract manufacturing and development solutions. It provides commercial mammalian and microbial production, clinical development, and manufacturing services. It also provides active pharmaceutical components with high potential, cell and gene therapy capabilities, sophisticated intermediates, oral medication product development services, cell culture models, genome editing, endotoxin products, and research media and testing goods. Lonza offers health and well-being solutions, microbiological and hygiene management, composites, and material protection. The corporation has production and research and development centers throughout Asia, Europe, and the Americas. Lonza is based in Basel, Switzerland.
The American Type Culture Collection (ATCC) is an important medical research resource. It is the world's foremost storehouse of biological cultures. Through in-house initiatives and collaborative collaborations, the ATCC conducts research to improve the propagation, preservation, categorization, and characterization of cultures, as well as to generate new and improved culture products. The ATCC was founded in 1925 and is presently located in Manassas, Virginia.Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size | USD 2.18 Billion |
CAGR | 13.9% |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product, Technique, and Application |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Thermo Fisher Scientific Inc., Promocell GmbH |
Key Market Opportunities | Increasing R&D expense and new product launches |
Key Market Drivers | Growing concerns over cell culture contamination |
The mycoplasma testing market is projected to grow at an 13.9% CAGR during the forecast period.
The Americas is projected to command the largest share in the mycoplasma testing market.
It is widely used in lot release testing, virus testing, and others.
New product launches and increasing R&D expenditure is adding market growth.
Availability of alternatives may limit market growth.